Skip to main content

Top in cardiology

Top in cardiology: Atherosclerosis common in lung cancer; treating amyloidosis

Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed.

According to a presentation given at the American College of Cardiology’s Advancing theCardiovascular Care of the Oncology Patient course, more than three-quarters of patients entering lung cancer treatment who underwent chest CT imaging showed evidence of atherosclerosis.


White patients who smoked appeared most likely to have atherosclerosis on CT out of all the subgroups examined, researchers found.

“What this study confirms is that tobacco use is a shared risk factor for both diseases and at the time of lung cancer diagnosis these patients should be considered for additional evaluation by a cardiologist or cardio-oncologist, as it is likely they already have CV disease,” Christopher Malozzi, DO, director of cardio-oncology services at the University of South Alabama Frederick P. Whiddon College of Medicine, told Healio.

It was the top story in cardiology last week. In another top story, Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, discussed the evolving treatment landscape of amyloidosis.

Read these and more top stories in cardiology below:

High prevalence of atherosclerosis detected in patients entering lung cancer therapy

cardiology, heart disease, cardiovascular health, arrhythmia, heart attack, stroke, hypertension, atherosclerosis, heart failure, echocardiography, angioplasty, stent placement, cardiac arrest, electrophysiology, myocarditis, cardiomyopathy, cholesterol, blood pressure, coronary artery disease, cardiovascular research,

#Cardiology #HeartHealth #CardiovascularDisease #HeartAttack #Stroke #Hypertension #Atherosclerosis #HeartFailure #Echocardiography #Angioplasty #StentPlacement #CardiacArrest #Electrophysiology #Myocarditis #Cardiomyopathy #Cholesterol #BloodPressure #CoronaryArteryDisease #HeartCare #CardiovascularResearch


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...